GENETIC TECHNOLOGIES LIMITED

==> picture [596 x 145] intentionally omitted <==

ASX ANNOUNCEMENT 25 November 2014

2014 Annual General Meeting

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release the attached slide show presentation which will be delivered by its Chief Executive Officer, Ms. Alison Mew, at the Company’s 2014 Annual General Meeting to be held at approximately 10.40 am this morning in the “Treetops” Room at Melbourne Museum, 11 Nicholson Street, Carlton, Victoria, Australia.

FOR FURTHER INFORMATION PLEASE CONTACT

Dr. Malcolm R. Brandon Chairman Genetic Technologies Limited (ABN 17 009 212 328) Telephone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : [email protected] ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Annual General Meeting Tuesday, 25 November 2014

==> picture [439 x 76] intentionally omitted <==

----- Start of picture text -----

Forward Looking Statements
----- End of picture text -----

This presentation may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934 with respect to the financial condition, results and business achievements/performance of Genetic Technologies Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Genetic Technologies Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Genetic Technologies’ current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.

==> picture [443 x 63] intentionally omitted <==

Strategic Review of GTG business and growth opportunities
Phenogen strategic shift and focus on breast and imaging centers to accelerate growth
Development and launch of BREVAGen plus in October 2014
Clinical Utility studies for BREVAGen plus designed – with payer and physician feedback
Divestment of Heritage genetic testing businesses to Specialist Diagnostics Services (a subsidiary of Primary Healthcare): completed November 2014.
Divestment of other non-core assets:
Gtech reverse merger to Simavita
ImmunAid share swap

==> picture [272 x 77] intentionally omitted <==

----- Start of picture text -----

Strategic Review
----- End of picture text -----

Board and Management review of company assets:
Heritage businesses – little opportunity for growth, sample numbers trending downwards
RareCellect – technology being superseded, patent portfolio costly, time limit on divestment activities
Divestment of other non-core assets
Licensing program – changing landscape in US courts, European up - front costs, patents at the end of life
BREVAGen – major asset with opportunity and scope for growth; rapid development of new generation product.

==> picture [304 x 77] intentionally omitted <==

----- Start of picture text -----

What is BREVAGen
----- End of picture text -----

==> picture [68 x 77] intentionally omitted <==

----- Start of picture text -----

?
----- End of picture text -----

BREVAGen plus is a simple swab-based test that can help determine a woman’s risk of developing breast cancer
Genetic risk is combined with clinical risk from the Breast Cancer Risk Assessment Tool (“BCRAT”) to provide an integrated risk score
Molecular panel of over 70 SNPs (single nucleotide polymorphisms) identified from the Human Genome Project
Found in 25-50% of women, these SNPs are high frequency/low penetrance alleles
First test of its kind to be clinically validated to assess both five-year and lifetime risk for sporadic breast cancer
Validated and CLIA-approved for use in Caucasian women of European descent, Hispanic and African American women aged ≥ 35

==> picture [327 x 326] intentionally omitted <==

Provides a >20% increase in accuracy over 1[st] generation BREVAGen

==> picture [340 x 77] intentionally omitted <==

----- Start of picture text -----

Launching BREVAGen
----- End of picture text -----

==> picture [53 x 77] intentionally omitted <==

Launched 6 October 2014
Featured on 17 news affiliates - television segments across the country
Radio news features and talkback health programs
Multimedia and websites eg. Yahoo! Finance, Reuters
Print media – trade publications, national and local news media
Social media – Facebook, Twitter, LinkedIn
Posters and pamphlets for physician offices
Logistics: swap of kits, training of clinic staff
Key validation data on Hispanics and African American populations - will be made available to physicians, prior to journal publication

==> picture [269 x 77] intentionally omitted <==

----- Start of picture text -----

Media Coverage
----- End of picture text -----

The BREVAGen plus logo with the tagline was seen on the Reuters billboard in Times Square from October 6 – 8.
To-date, the news release has resulted in:
6,699 online views
1,540 online video views
32 total file downloads (images, video, etc.)

==> picture [255 x 386] intentionally omitted <==

Traditional

Customer Type

Strategic

‘Key Account’ ‘Strategic Account’ Independent High-Potential Breast/Imaging Centers MDs MD groups

65%

35%

Regional Business Manager

Regional Business Manager + Director Strategic Accounts

==> picture [534 x 57] intentionally omitted <==

----- Start of picture text -----

Strategic Accounts: To commence Nov 2014– January
----- End of picture text -----

==> picture [145 x 81] intentionally omitted <==

----- Start of picture text -----

Breast/Imaging
Centers
----- End of picture text -----

West Region

Good Samaritan (CA)
Pink Lotus (CA)
St Johns (CA)
Aurora Breast Center (WI)
• Creighton (NE)
Evergreen (WA)
St Luke’s (KS)

East Region

Atlantic Healthcare System (NJ)
Breast Care Partners (NY)
VitalMD (FL)
• KBEC (OH)
Capital Imaging (PA)
Pinnacle Breast Group (PA)
Exempla (CO)

==> picture [644 x 72] intentionally omitted <==

----- Start of picture text -----

Spreading the Story: Conference Exhibits 2014
----- End of picture text -----

Miami Breast Cancer Conference (Feb 2014)

 National Consortium of Breast Centers (March 2014)

 Take the Lead in Breast Cancer Care (April & Nov 2014)  American Society of Breast Surgeons (May 2014)  Sister’s Network: Annual National African-American Breast Cancer Conference (Oct 2014)

 Nurse Practitioners in Women’s Health (Oct 2014)

 Univ of Florida Symposium on Breast Disease (Feb 2014)

 Next Generation of Breast Centers - IL(March 2014)

 World Class Imaging Conference - NC (April 2014)

Survival Skills for Today's Gynecologist - NY (May 2014)

==> picture [579 x 65] intentionally omitted <==

----- Start of picture text -----

Spreading the Story: Conference Exhibits
----- End of picture text -----

New Jersey OBGYN Society (June 2014)
Colorado ACOG Section Meeting (June 2014)
Utah Association of Genetic Counselors (June 2014)
Omnia Education Women’s Health Visit Series (Multiple metropolitan areas, 2014)
Advanced Practice in Primary Care – WA (Oct 2014)
Illinois Society for Advanced Practice Nurses (Oct 2014)  Baptist Health Breast Cancer Symposium – FL (Oct 2014)  Breast Cancer Symposium, Albany NY (Oct 2014)  Pinnacle Health OBGYN Conference – PA (Oct 2014)

==> picture [582 x 72] intentionally omitted <==

----- Start of picture text -----

Geographical Clustering of Samples: 2014
----- End of picture text -----

==> picture [661 x 351] intentionally omitted <==

==> picture [666 x 72] intentionally omitted <==

----- Start of picture text -----

BREVAGen sample growth: Performance to date
----- End of picture text -----

==> picture [651 x 364] intentionally omitted <==

==> picture [273 x 76] intentionally omitted <==

==> picture [53 x 76] intentionally omitted <==

Additional studies Clinical Utility Studies to Claim denials due to published to include: drive MRI and/or “Experimental and • chemoprevention Investigational” Hispanic American • African American • Expanded SNP panel Inclusion of BREVAGen in Experimental and Investigational NCCN Committee appeals package submitted Guidelines Contract directly with large Self-Insured Employer Contract directly with Groups Insurers Contracting with Patient Protection PPOs Program underpins revenue received Improved BREVAGen Reimbursement

==> picture [307 x 77] intentionally omitted <==

----- Start of picture text -----

Key Market Drivers
----- End of picture text -----

 Validation and Clinical Utility

Additional clinical validation publications expected in early to mid 2015:
Expanded SNP panel, Caucasians, African American and Hispanic
Clinical utility studies, conducted in association with key breast centers, will increase reimbursement and speed of product uptake – to commence Q3 FY2015

 Market Awareness

KOL speaker program; Integrated web/social media; targeted regional media features
- BREVAGen plus launch coincided with Breast Cancer Awareness month: Oct 2014
Key Accounts (with a focus on Breast/Imaging Centers)
Establish and Grow

 Reimbursement

Commence negotiations with Insurers once clinical utility studies provide supporting data

==> picture [720 x 540] intentionally omitted <==

----- Start of picture text -----

FY15-FY18: Bending the Curve ...
45000
41000
40000
35000
30000
25000
25000
20000
16000
15000
9300
10000
5000 3936
1542
415
0
Year 1 Year 2 Year 3 Year 4 (This FY) Year 5 Year 6 Year 7
17
----- End of picture text -----

==> picture [325 x 77] intentionally omitted <==

----- Start of picture text -----

Priorities for FY2015
----- End of picture text -----

Strengthen the Phenogen sales team, focus on improving scalability and market awareness of BREVAGen plus
Find, establish and grow key accounts (breast centers, radiology centers) in the U.S. market
Monitor the release of 2[nd] generation BREVAGen plus to improve performance, expand market reach, increase market acceptance and brand awareness
Continue to work with payers (insurers) to improve reimbursement outcomes
Manage operating cost base and cash flow with the aim of maximising re-investment in product development and top line growth
Ensure adequate funding is available to meet objectives
Research and Development: Develop additional products for different disease states eg. colon cancer

AI assistant

GENETIC TECHNOLOGIES LIMITED AGM Information 2014

65022_rns_2014-11-24_856db948-1302-4e92-9660-dd8c986d7912.pdf

2014 Annual General Meeting